Get the Stockscreener App
344.56
0.34%
-1.165
After Hours:
344.44
-0.125
-0.04%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $344.56, with a volume of 3.39M.
It is down -0.34% in the last 24 hours and up +3.88% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$345.73
Open:
$348.24
24h Volume:
3.39M
Relative Volume:
1.32
Market Cap:
$185.96B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
23.96
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+4.97%
1M Performance:
+3.88%
6M Performance:
+9.79%
1Y Performance:
+18.82%
1-Day Range:
$342.62
$349.64
1-Week Range:
$325.98
$356.50
52-Week Range:
$267.83
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
344.56 | 186.59B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,144.68 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
237.00 | 558.86B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
225.42 | 394.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.60 | 295.19B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
149.12 | 279.38B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Morgan Stanley raises Amgen stock price target on obesity drug potential - Investing.com Canada
Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure - Yahoo Finance
Is It Too Late To Consider Amgen (AMGN) After Its Strong Multi Year Share Price Run? - Yahoo Finance
Amgen Inc. $AMGN Shares Purchased by LPL Financial LLC - MarketBeat
Franklin Resources Inc. Has $712.09 Million Stake in Amgen Inc. $AMGN - MarketBeat
Cerity Partners LLC Has $134.82 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Goldman Sachs Trims Amgen (AMGN) Valuation but Sticks with Buy Rating - Yahoo Finance
Amgen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Amgen stock (US0311621009): FDA filing and pipeline momentum in focus - AD HOC NEWS
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Why Amgen Inc (AMGN) Is Set to Outperform the Market: Insights i - GuruFocus
AMGN DCF Analysis: Intrinsic Value $292 vs Price $350 - GuruFocus
Can MariTide Save Amgen Stock From Its Fading Blockbusters? - Trefis
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
O Shaughnessy Asset Management LLC Buys 27,035 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. stock (US0311621009): Weight-loss pipeline and Horizon deal keep biotech in focus - AD HOC NEWS
Hilton Head Capital Partners LLC Purchases Shares of 3,798 Amgen Inc. $AMGN - MarketBeat
Los Angeles Capital Management LLC Decreases Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by Erste Asset Management GmbH - MarketBeat
Brandywine Global Investment Management LLC Has $140 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Unveils Promising Data on Diabetes at ADA Conferenc - GuruFocus
Diabetes patients on Repatha saw fewer first heart attacks and strokes - Stock Titan
What to know about MariTide, Amgen’s experimental GLP-1 drug - AOL.com
Should Amgen’s (AMGN) IMDYLLTRA Win and Rare-Disease Data Shift Its High-Need Portfolio Strategy? - simplywall.st
PBU The Pension Fund of Early Childhood & Youth Educators Acquires Shares of 21,624 Amgen Inc. $AMGN - MarketBeat
Capital International Investors Decreases Stock Position in Amgen Inc. $AMGN - MarketBeat
Capital International Inc. CA Has $139.28 Million Position in Amgen Inc. $AMGN - MarketBeat
Capital World Investors Boosts Holdings in Amgen Inc. $AMGN - MarketBeat
Capital Research Global Investors Cuts Position in Amgen Inc. $AMGN - MarketBeat
Capital International Sarl Has $28.77 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Capital Group Investment Management PTE. LTD. Reduces Position in Amgen Inc. $AMGN - MarketBeat
Capital Group Private Client Services Inc. Acquires 4,879 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Stock Revenue Hit $8.6 Billion in Q1 as UPLIZNA Surged 188% and Repatha Hit a New Run Rate. Here’s What it Means for the Stock - TIKR.com
When Culture Meets Care: Bringing Cardiovascular Screening to the Heart of New Orleans - Amgen
Vestcor Inc Sells 10,133 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Position Boosted by Vise Technologies Inc. - MarketBeat
MCF Advisors LLC Increases Position in Amgen Inc. $AMGN - MarketBeat
J.W. Cole Advisors Inc. Sells 6,407 Shares of Amgen Inc. $AMGN - MarketBeat
Fjarde AP Fonden Fourth Swedish National Pension Fund Cuts Stake in Amgen Inc. $AMGN - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Has $25.04 Million Position in Amgen Inc. $AMGN - MarketBeat
Does Amgen Stock's Recent Strength Signal Real Portfolio Diversification? - Trefis
Amgen (NASDAQ:AMGN) Cut to Hold at Wall Street Zen - MarketBeat
Assessing Whether Amgen (AMGN) Is Slightly Undervalued After Recent Share Price Gains - Yahoo Finance
Amgen: A Biotech Giant's Path to Recovery and Growth - The Globe and Mail
Is Amgen An Undervalued Stock Or Value Trap? - Yahoo Finance
Amgen Inc. (AMGN) Announces EC’s Grant of Marketing Authorization for IMDYLLTRA® - Insider Monkey
Key Study for Amgen’s Tavneos Under Investigation at Journal - Bloomberg
Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Goldman Sachs Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $389 - Moomoo
Amgen upgraded to cautious Buy on strong pipeline and growth potential despite recent stock weakness. - Pluang
Is There Still Opportunity In Amgen (AMGN) After Its 24% One-Year Share Price Gain - simplywall.st
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.85%
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):